摘要
Abstract
Objective To observe the clinical efficacy and safety of sorafenib combined with chemotherapy for hepatocellular carcinoma. Methods 56 patients with Hepatocelular Carcinoma admitted in our hospital from February 2003 to February 20l0,were randomly divided into the treatment group and the control.The treatment group was interfered with sorafenib combined with EF;The control group was treated with sorafenib. Overall efficacy and incidence of adverse reactions were compared. Results The treatment group is more efficacy than the control group in The effective rate (CR+PR),control rate,median follow-up time,median progression-free survival (PFS),median survival (OS)and 1 year survival rate is better in treatment than those in the control,The difference was statistically significant (P<0.05).The major adverse reactions in both groups were fatigue,hypertension,hand-foot skin reaction,diarrhea,etc.In addition,leukopenia,nausea and vomiting were more popular than those in the control(P<0.05),other adverse reactions in both groups were not statistically significant(P > 0.05). Conclusion Sorafenib combined with (EF program) chemotherapy was more efficacy,safety,and well tolerated in the treatment of HepatocelIular Carcinoma.关键词
索拉非尼/化疗治疗/原发性肝癌Key words
Sorafenib/Chemotherapy/Hepato cellular carcinoma分类
医药卫生
